As biotech recovers, venture firms’ preferences appear to shift
After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. For one,
July 8, 2024
After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. For one,
Today, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO’s annual meeting in San
Long dismissed by top scientists and drug regulators, the use of psychedelics to treat mental health conditions has finally gained
Dive Brief: Expert advisers to the Food and Drug Administration will need to weigh whether Eli Lilly’s experimental Alzheimer’s disease
Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. British drugmaker
Dive Brief: Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior
Today, a brief rundown of news from Eli Lilly, Cytokinetics and AbbVie, as well as updates from Gilead and the
Dive Brief: Illumina’s board of directors has approved a spinoff of Grail, targeting June 24 as the date the cancer
Medical experts who advise the Food and Drug Administration are not convinced MDMA is ready for general use to help
Dive Brief: An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months,